Clinical trial
A Prospective Exploratory Study of the Safety and Preliminary Efficacy of the α-Syn H21 Monoclonal Antibody in Patients With Multiple System Atrophy
NCT07774585 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective Exploratory Study of the Safety and Preliminary Efficacy of the α-Syn H21 Monoclonal Antibody in Patients With Multiple System Atrophy
- Lead sponsor
- Ruijin Hospital
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- September 15, 2026
- Completion date
- December 31, 2026
- Enrollment
- 3 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.